Home >

Icotinib (Conmana)

Last Updated: 03/13/18

Status: Currently a NF2 Clinical Trial

Chemical Structure, Icotinib

Trade Name: Conmana
Synonyms: Icotinib hydrochloride (BPI-2009H), 610798-31-7, Conmana, BPI-2009, UNII-9G6U5L461Q, BPI-2009H,
CHEMBL2087361, N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine,
Pharmaceutical Company:
Legal Status: ℞ - Prescription, in China, Beijing
Administered By: Pill - Oral
Tumor Target: NF2 Vestibular Schwannoma, solid tumors
Protein Target: Epidermal Growth Factor Receptor -
Tyrosine Kinase Inhibitor (EGFR-TKI)
Formula: C22H22ClN3O4
NF2 Trial: Recruiting Trial: NCT02934256
PubChem CID 44609731
ChemSpider 28637803


  1. Peng, Li. ClinicalTrials.gov. NIH - U. National Library of Medicine. "Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors" (2016) Clinical Trials.
    Source: https://clinicaltrials.gov/ct2/show/NCT02934256
  2. Hu, Shaojing, et al. Bioorganic & medicinal chemistry letters "Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors." 22.19 (2012): 6301-6305.
    Source: https://www.sciencedirect.com/science/article/pii/S0960894X12008189 | DOI: 10.1016/j.bmcl.2012.06.067